Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 589 to 593 of 593 entries
Sorted by: Best Match Show Resources per page
Crowding within synaptic junctions influence the degradation of adenoside nucleotides by CD39 and CD73 ectonucleotidases.

Biophysical journal

Rahmaninejad H, Pace T, Chun BJ, Kekenes-Huskey P.
PMID: 34922916
Biophys J. 2021 Dec 16; doi: 10.1016/j.bpj.2021.12.013. Epub 2021 Dec 16.

Synapsed cells can communicate using exocytosed nucleotides like adenosine triphosphate (ATP). Ectonucleotidases localized to synaptic junctions degrade nucleotides into metabolites like adenosine monophosphate(AMP) or adenosine. Oftentimes nucleotide degradation occures in a sequential manner, of which ATP degradation by CD39...

Cite
Rahmaninejad H, Pace T, Chun BJ, et al. Crowding within synaptic junctions influence the degradation of adenoside nucleotides by CD39 and CD73 ectonucleotidases. Biophys J. 2021;doi: 10.1016/j.bpj.2021.12.013.
Rahmaninejad, H., Pace, T., Chun, B. J., & Kekenes-Huskey, P. (2021). Crowding within synaptic junctions influence the degradation of adenoside nucleotides by CD39 and CD73 ectonucleotidases. Biophysical journal, . https://doi.org/10.1016/j.bpj.2021.12.013
Rahmaninejad, Hadi, et al. "Crowding within synaptic junctions influence the degradation of adenoside nucleotides by CD39 and CD73 ectonucleotidases." Biophysical journal vol. (2021). doi: https://doi.org/10.1016/j.bpj.2021.12.013
Rahmaninejad H, Pace T, Chun BJ, Kekenes-Huskey P. Crowding within synaptic junctions influence the degradation of adenoside nucleotides by CD39 and CD73 ectonucleotidases. Biophys J. 2021 Dec 16; doi: 10.1016/j.bpj.2021.12.013. Epub 2021 Dec 16. PMID: 34922916.
Copy Download .nbib Format: NLM
Platelet function in dogs with chronic liver disease.

The Journal of small animal practice

Wilkinson A, Panciera D, DeMonaco S, Boes K, Leib M, Clapp K, Ruth J, Cecere T, McClendon D.
PMID: 33900656
J Small Anim Pract. 2021 Apr 26; doi: 10.1111/jsap.13342. Epub 2021 Apr 26.

OBJECTIVES: To assess platelet function, buccal mucosal bleeding time and plasma von Willebrand factor concentration in dogs with chronic inflammatory and/or fibrotic liver disease and to compare results with those obtained in healthy dogs.MATERIALS AND METHODS: Preliminary study including...

Cite
Wilkinson A, Panciera D, DeMonaco S, et al. Platelet function in dogs with chronic liver disease. J Small Anim Pract. 2021;doi: 10.1111/jsap.13342.
Wilkinson, A., Panciera, D., DeMonaco, S., Boes, K., Leib, M., Clapp, K., Ruth, J., Cecere, T., & McClendon, D. (2021). Platelet function in dogs with chronic liver disease. The Journal of small animal practice, . https://doi.org/10.1111/jsap.13342
Wilkinson, A, et al. "Platelet function in dogs with chronic liver disease." The Journal of small animal practice vol. (2021). doi: https://doi.org/10.1111/jsap.13342
Wilkinson A, Panciera D, DeMonaco S, Boes K, Leib M, Clapp K, Ruth J, Cecere T, McClendon D. Platelet function in dogs with chronic liver disease. J Small Anim Pract. 2021 Apr 26; doi: 10.1111/jsap.13342. Epub 2021 Apr 26. PMID: 33900656.
Copy Download .nbib Format: NLM
Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models.

Hepatology (Baltimore, Md.)

Johnston ME, Rivas MP, Nicolle D, Gorse A, Gulati R, Kumbaji M, Weirauch MT, Bondoc A, Cairo S, Geller J, Tiao G, Timchenko N.
PMID: 34037269
Hepatology. 2021 Oct;74(4):2201-2215. doi: 10.1002/hep.31919. Epub 2021 Aug 10.

BACKGROUND AND AIMS: Hepatoblastoma (HBL) is a devastating pediatric liver cancer with multiple treatment options, but it ultimately requires surgery for a cure. The most malicious form of HBL is a chemo-resistant aggressive tumor that is characterized by rapid...

Cite
Johnston ME, Rivas MP, Nicolle D, et al. Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models. Hepatology. 2021;74(4):2201-2215doi: 10.1002/hep.31919.
Johnston, M. E., Rivas, M. P., Nicolle, D., Gorse, A., Gulati, R., Kumbaji, M., Weirauch, M. T., Bondoc, A., Cairo, S., Geller, J., Tiao, G., & Timchenko, N. (2021). Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models. Hepatology (Baltimore, Md.), 74(4), 2201-2215. https://doi.org/10.1002/hep.31919
Johnston, Michael Edward, et al. "Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models." Hepatology (Baltimore, Md.) vol. 74,4 (2021): 2201-2215. doi: https://doi.org/10.1002/hep.31919
Johnston ME, Rivas MP, Nicolle D, Gorse A, Gulati R, Kumbaji M, Weirauch MT, Bondoc A, Cairo S, Geller J, Tiao G, Timchenko N. Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models. Hepatology. 2021 Oct;74(4):2201-2215. doi: 10.1002/hep.31919. Epub 2021 Aug 10. PMID: 34037269; PMCID: PMC8463483.
Copy Download .nbib Format: NLM
Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC.

Cancer letters

Sun C, Jing W, Xiong G, Ma D, Lin Y, Lv X, Zhao Y, Ma X, Zhu L, Shen X, Yang M, Qin Z, Cheng Y, Xuan H, Li T, Han L.
PMID: 34762994
Cancer Lett. 2021 Nov 08;526:180-192. doi: 10.1016/j.canlet.2021.11.005. Epub 2021 Nov 08.

Hepatocellular carcinoma (HCC), a heterogeneous cancer with high mortality, is resistant to single targeted therapy; thus, combination therapy based on synthetic lethality is a promising therapeutic strategy for HCC. Poly (adenosine diphosphate [ADP]-ribose) polymerase 1 (PARP1) is the most...

Cite
Sun C, Jing W, Xiong G, et al. Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC. Cancer Lett. 2021;526:180-192doi: 10.1016/j.canlet.2021.11.005.
Sun, C., Jing, W., Xiong, G., Ma, D., Lin, Y., Lv, X., Zhao, Y., Ma, X., Zhu, L., Shen, X., Yang, M., Qin, Z., Cheng, Y., Xuan, H., Li, T., & Han, L. (2021). Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC. Cancer letters, 526180-192. https://doi.org/10.1016/j.canlet.2021.11.005
Sun, Caiyu, et al. "Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC." Cancer letters vol. 526 (2021): 180-192. doi: https://doi.org/10.1016/j.canlet.2021.11.005
Sun C, Jing W, Xiong G, Ma D, Lin Y, Lv X, Zhao Y, Ma X, Zhu L, Shen X, Yang M, Qin Z, Cheng Y, Xuan H, Li T, Han L. Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC. Cancer Lett. 2021 Nov 08;526:180-192. doi: 10.1016/j.canlet.2021.11.005. Epub 2021 Nov 08. PMID: 34762994.
Copy Download .nbib Format: NLM
Impact of Primary Hemostasis Disorders on Late Major Bleeding Events among Anticoagulated Atrial Fibrillation Patients Treated by TAVR.

Journal of clinical medicine

Dietrich L, Kibler M, Matsushita K, Marchandot B, Trimaille A, Reydel A, Diop B, Truong PD, Trung AM, Trinh A, Carmona A, Hess S, Jesel L, Ohlmann P, Morel O.
PMID: 35011952
J Clin Med. 2021 Dec 31;11(1). doi: 10.3390/jcm11010212.

BACKGROUND: Bleeding events are among the striking complications following transcatheter aortic valve replacement (TAVR), and bleeding prediction models are crucially warranted. Several studies have highlighted that primary hemostasis disorders secondary to persistent loss of high-molecular-weight (HMW) multimers of the...

Cite
Dietrich L, Kibler M, Matsushita K, et al. Impact of Primary Hemostasis Disorders on Late Major Bleeding Events among Anticoagulated Atrial Fibrillation Patients Treated by TAVR. J Clin Med. 2021;11(1)doi: 10.3390/jcm11010212.
Dietrich, L., Kibler, M., Matsushita, K., Marchandot, B., Trimaille, A., Reydel, A., Diop, B., Truong, P. D., Trung, A. M., Trinh, A., Carmona, A., Hess, S., Jesel, L., Ohlmann, P., & Morel, O. (2021). Impact of Primary Hemostasis Disorders on Late Major Bleeding Events among Anticoagulated Atrial Fibrillation Patients Treated by TAVR. Journal of clinical medicine, 11(1), . https://doi.org/10.3390/jcm11010212
Dietrich, Laurent, et al. "Impact of Primary Hemostasis Disorders on Late Major Bleeding Events among Anticoagulated Atrial Fibrillation Patients Treated by TAVR." Journal of clinical medicine vol. 11,1 (2021). doi: https://doi.org/10.3390/jcm11010212
Dietrich L, Kibler M, Matsushita K, Marchandot B, Trimaille A, Reydel A, Diop B, Truong PD, Trung AM, Trinh A, Carmona A, Hess S, Jesel L, Ohlmann P, Morel O. Impact of Primary Hemostasis Disorders on Late Major Bleeding Events among Anticoagulated Atrial Fibrillation Patients Treated by TAVR. J Clin Med. 2021 Dec 31;11(1). doi: 10.3390/jcm11010212. PMID: 35011952; PMCID: PMC8746148.
Copy Download .nbib Format: NLM
Showing 589 to 593 of 593 entries